Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.

MLA

Galema-Boers, Annette M. H., et al. “Proprotein Convertase Subtilisin/Kexin 9 Inhibition in Patients with Familial Hypercholesterolemia: Initial Clinical Experience.” Journal of Clinical Lipidology, vol. 11, no. 3, May 2017, pp. 674–81. EBSCOhost, https://doi.org/10.1016/j.jacl.2017.02.014.

APA

Galema-Boers, A. M. H., Lenzen, M. J., Sijbrands, E. J., & Roeters van Lennep, J. E. (2017). Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. Journal of Clinical Lipidology, 11(3), 674–681. https://doi.org/10.1016/j.jacl.2017.02.014

Chicago

Galema-Boers, Annette M.H., Mattie J. Lenzen, Eric J. Sijbrands, and Jeanine E. Roeters van Lennep. 2017. “Proprotein Convertase Subtilisin/Kexin 9 Inhibition in Patients with Familial Hypercholesterolemia: Initial Clinical Experience.” Journal of Clinical Lipidology 11 (3): 674–81. doi:10.1016/j.jacl.2017.02.014.